FDA postpones key hearing on biosimilar copy of blockbuster drug

February 26, 2015 12:39 PM

9 0

(Reuters) - The U.S. Food and Drug Administration has postponed a crucial meeting of an advisory committee to consider a cheap version of a top-selling drug for rheumatoid arthritis and Crohn's disease, which had been scheduled for March 17.

The U.S. regulator said in a statement on its website late on Wednesday that the hearing was postponed "due to information requests pending with the sponsor of the application".

Also read: Rio Tinto Rejects Glencore’s $2.5 Billion Offer in Favor of Yancoal

Read more

To category page

Loading...